On behalf of the Japanese Society of Nephrology Task Force for the Validation of Urine Examination as a Universal Screening.
Our recently published cost-effectiveness study on chronic kidney disease mass screening test in Japan evaluated the use of dipstick test, serum creatinine (Cr) assay or both in specific health checkup (SHC). Mandating the use of serum Cr assay additionally, or the continuation of current policy mandating dipstick test only was found cost-effective. This study aims to examine the affordability of previously suggested reforms.
Budget impact analysis was conducted assuming the economic model would be good for 15 years and applying a population projection. Costs expended by social insurers without discounting were counted as budgets.
Annual budget impacts of mass screening compared with do-nothing scenario were calculated as ¥79–¥−1,067 million for dipstick test only, ¥2,505–¥9,235 million for serum Cr assay only and ¥2,517–¥9,251 million for the use of both during a 15-year period. Annual budget impacts associated with the reforms were calculated as ¥975–¥4,129 million for mandating serum Cr assay in addition to the currently used mandatory dipstick test, and ¥963–¥4,113 million for mandating serum Cr assay only and abandoning dipstick test.
Estimated values associated with the reform from ¥963–¥4,129 million per year over 15 years are considerable amounts of money under limited resources. The most impressive finding of this study is the decreasing additional expenditures in dipstick test only scenario. This suggests that current policy which mandates dipstick test only would contain medical care expenditure.
El Nahas AM, Bello AK. Chronic kidney disease: the global challenge. Lancet. 2005;365:331–440. CrossRef
Levey AS, Schoolwerth AC, Burrows NR, Williams DE, Stith KR, McClellan W, et al. Comprehensive public health strategies for preventing the development, progression, and complications of CKD: report of an expert panel convened by the centers for disease control and prevention. Am J Kidney Dis. 2009;53:522–35. PubMedCrossRef
Iseki K. Role of urinalysis in the diagnosis of chronic kidney disease (CKD). JMAJ. 2011;54:27–30.
Li PK, Chow KM, Matsuo S, Yang CW, Jha V, Becker G, et al. Asian chronic kidney disease best practice recommendations: positional statements for early detection of chronic kidney disease from Asian forum for chronic kidney disease initiatives (AFCKDI). Nephrology (Carlton). 2011;16:633–41. PubMed
Tsukamoto Y, Wang H, Becker G, Chen HC, Han DS, Harris D, et al. Report of the Asian Forum of Chronic Kidney Disease Initiative (AFCKDI) 2007. Current status and perspective of CKD in Asia: diversity and specificity among Asian countries. Clin Exp Nephrol. 2009; 13:249–56.
Seino Y. New diagnostic criteria for diabetes in Japan. Nippon Rinsho. 2010;68:2357–61. PubMed
Culyer AJ. The dictionary of health economics. 2nd ed. Cheltenham: Edward Elger; 2010. CrossRef
National Institute of Population and Social Security Research Tokyo, Japan. Population projections for Japan—a supplement to the 2006 revision—(commentary with ancillary projections). Tokyo: Health and Welfare Statistics Association. 2008.
Ministry of Health, Labour and Welfare. Heisei 20 nendo tokutei kenko shinsatokutei hoken shidono jisshi jyokyo ni tsuite. Tokyo: Ministry of Health, Labour and Welfare. 2010.
Ministry of Health, Labour and Welfare. Estimates of National Medical Care Expenditure 2010. Tokyo: Ministry of Health, Labour and Welfare. 2013.
Peralta CA, Shlipak MG, Judd S, Cushman M, McClellan W, Zakai NA, et al. Detection of chronic kidney disease with creatinine, cystatin C, and urine albumin-to-creatinine ratio and association with progression to end-stage renal disease and mortality. JAMA. 2011;305:1545–52. PubMedCentralPubMedCrossRef
- Budget impact analysis of chronic kidney disease mass screening test in Japan
- Springer Japan
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II